Summary
Kiadis Pharma NV (Kiadis) is a biopharmaceutical company that develops and markets cell-based immunotherapy products for the treatment of blood cancers and inherited blood disorders. The company offers cellular products including ATIR101 and ATIR201 for infusion. Its ATIR101 lowers the risks and limitations in blood cancers, cancer relapse, opportunistic infections, and limited donor availability. Kiadis develops ATIR201 for the treatment of thalassemia. Its product candidates are produced using the proprietary TH9402 compound which selectively targets and depletes rapidly dividing cells such as immune reactive cells in a mixed lymphocyte reaction between donor and patient material. The company uses theralux platform to develop therapeutic products. Its products serve the needs of patients suffering from hematological malignancies and blood cancer transplant. Kiadis is headquartered in Amsterdam, the Netherlands.

Kiadis Pharma NV Key Recent Developments

Feb 15,2021: Kiadis issues shares to Kreos Capital following agreed conversion of convertible bonds
Feb 12,2021: Sanofi launches recommended cash offer for all shares in Kiadis
Jan 22,2021: Kiadis announces multiple abstracts related to its K-NK-cell therapy platform have been accepted for presentation at TCT, the Combined Transplantation and Cellular Therapy Meetings of ASTCT and CIBMTR
Jan 14,2021: Kiadis draws €20 million from bridge loan with Sanofi
Dec 06,2020: Kiadis announces new data at the 2020 ASH Annual Meeting and Exposition

This comprehensive SWOT profile of Kiadis Pharma NV provides you an in-depth strategic analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

This company report forms part of GlobalData’s ‘Profile on Demand’ service, covering over 50,000 of the world’s leading companies. Once purchased, GlobalData’s highly qualified team of company analysts will comprehensively research and author a full financial and strategic analysis of Kiadis Pharma NV including a detailed SWOT analysis, and deliver this direct to you in pdf format within two business days. (excluding weekends).

The profile contains critical company information including*,

- Business description – A detailed description of the company’s operations and business divisions.
- Corporate strategy – Analyst’s summarization of the company’s business strategy.
- SWOT Analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
- Company history – Progression of key events associated with the company.
- Major products and services – A list of major products, services and brands of the company.
- Key competitors – A list of key competitors to the company.
- Key employees – A list of the key executives of the company.
- Executive biographies – A brief summary of the executives’ employment history.
- Key operational heads – A list of personnel heading key departments/functions.
- Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.
- Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
- Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Note*: Some sections may be missing if data is unavailable for the company.

Key benefits of buying this profile include,

You get detailed information about the company and its operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
- The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
- Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.
- Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.
- Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.